Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose–response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial

OBJECTIVES: To evaluate efficacy and safety of three different regimens of denosumab, a fully human monoclonal antibody to receptor activator of nuclear factor kappa B (RANK) ligand (RANKL), for Japanese patients with rheumatoid arthritis (RA). METHODS: In this multicentre, randomised, placebo-contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Tsutomu, Tanaka, Yoshiya, Ishiguro, Naoki, Yamanaka, Hisashi, Yoneda, Toshiyuki, Ohira, Takeshi, Okubo, Naoki, Genant, Harry K, van der Heijde, Désirée
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893103/
https://www.ncbi.nlm.nih.gov/pubmed/26585988
http://dx.doi.org/10.1136/annrheumdis-2015-208052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893103/
https://www.ncbi.nlm.nih.gov/pubmed/26585988
http://dx.doi.org/10.1136/annrheumdis-2015-208052

Ejemplares similares